Glenmark touts (much needed) $345M pain pact with Sanofi

Shares of India's Glenmark jumped on the news that Sanofi-Aventis has signed up for a $345 million partnership to develop new pain drugs. Glenmark gets $20 million upfront in the deal, along with royalties and a U.S. co-promotion agreement. Sanofi wins marketing rights in North America, Europe and Japan for TRPV3 and GRC 15300, two drugs in a new class of pain remedies. And Glenmark can use the occasion to mark an upbeat turn for the Mumbai-based developer, which has had to deal with...